Download
https://www.ndtvprofit.com/markets/cadila-healthcare-brokerages-divided-on-q4-performance-outlook?utm_source=telegram&utm_medium=referral&utm_campaign=socialshare
Analysts have mixed views on Cadila even as the company reported growth in Q4 and got approval for Covid drug.
Share